Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
Schett G, Mcinnes IB, Neurath M (2021)
Publication Type: Journal article, Review article
Publication year: 2021
Journal
Book Volume: 385
Pages Range: 628-639
Journal Issue: 7
Abstract
Immune-mediated inflammatory diseases (IMIDs) are a heterogeneous group of diseases characterized by chronic inflammation and organ damage. IMIDs were traditionally classified on the basis of the predominant organ involvement. Improving the pathogenic characterization of IMIDs, however, should allow for a refined mechanistic understanding of these diseases and should make it possible to develop a molecular-based classification. The transition from organ-based to molecular-based classification was initiated by insights into associated genetic mutations and polymorphisms of key immune pathways and the development of monoclonal antibodies that target signature cytokine hubs in IMIDs. As compared with an organ-based classification, molecular classification better addresses pathophysiological commonalities across IMIDs that affect different organs but also accounts for substantial mechanistic differences among IMIDs that affect the same organ (Fig. 1).
Authors with CRIS profile
Involved external institutions
United Kingdom (GB)How to cite
APA:
Schett, G., Mcinnes, I.B., & Neurath, M. (2021). Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. New England Journal of Medicine, 385(7), 628-639. https://dx.doi.org/10.1056/NEJMra1909094
MLA:
Schett, Georg, Iain B. Mcinnes, and Markus Neurath. "Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs." New England Journal of Medicine 385.7 (2021): 628-639.
BibTeX: Download